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The first description of Alzheimer’s disease (AD) was made in 1907 by Alois Alzheimer (Alzheimer 1907), 
although other contemporary physicians had made similar, and rather more complete, assessments of 
the neuropathological changes present in the AD brain (Fischer 1907).  Our knowledge of AD has 
increased dramatically and continues to accelerate.  This year is 25 years after the publication of a series 
of papers that, in various ways, articulated the amyloid cascade hypothesis (ACH) for AD (Hardy & Allsop 
1991, Beyreuther & Masters 1991, Selkoe 1991, Hardy & Higgins 1992).  This review will cover some 
familiar territory, but we shall also place the ACH into a wider context, compare it with other 
hypotheses for AD, explore the evolution of the hypothesis to encompass new findings, and determine, 
irrespective of the merits of the hypothesis itself, whether it has been useful for the research field, both 
in academia and in industry.  Finally, we shall review how the ACH has led to a number of therapeutic 
approaches, all of which have, to date, failed to reach their primary efficacy end-points in clinical trials 
and reflect upon what the future may hold. 
The hypothesis 
The major support for the ACH comes from the combination, and interdigitation, of pathophysiology 
and human genetics.  The origins of the ACH lie in the sequencing of the amino acid sequence of Aβ 
extracted from cerebral blood vessels (Glenner & Wong 1984b) and then brain parenchyma (Masters et 
al. 1985) of post mortem brains from AD patients.  This led to the identification and sequencing of the 
amyloid precursor protein (APP) gene (Kang et al. 1987) that encodes the holoprotein from which the Aβ 
peptide is excised by the sequential action of β-amyloid cleaving enzyme (BACE) to release the N- 
terminus of Aβ (Hussain et al. 1999, Sinha et al. 1999, Vassar et al. 1999, Yan et al. 1999, Lin et al. 2000) 
and γ-secretase that cleaves at the C-terminus (De Strooper et al. 1998, Wolfe et al. 1999b). γ-secretase  
is a multi-protein complex  comprised of Presenilin (PS)1 or PS2; aph1a or aph1b; Pen2 and nicastrin  
(for review, see (De Strooper et al. 2012)) with the PS proteins incorporating the enzyme’s active site 
aspartyl resides (Wolfe et al. 1999a, Wolfe et al. 1999b). Although other publications were articulating 
similar viewpoints, (Hardy & Allsop 1991, Selkoe 1991, Beyreuther & Masters 1991), the ACH was 
expounded most trenchantly in 1992 (Hardy & Higgins 1992).  In this admirably brief paper, the 
deposition of the Aβ peptide was portrayed as an upstream event in the evolution of AD, leading to cell 
death and/or the development of neurofibrillary tangles (NFTs) (hyper-phosphorylated, insoluble tau 
aggregates) via elevation of intracellular calcium ion levels. A critical component of the ACH comes from 
human genetics, where a family history of early onset AD led to a linkage analysis study that revealed a 
mutation resulting in a V717I amino acid change in the APP gene just C-terminal to the Aβ peptide 
sequence (Goate et al. 1991). This seminal work revealed that a single mutation resulted in early onset 
AD that was pathologically identical to sporadic, late onset AD.  The potential for a genetic cause for AD 
had been made previously: in 1984, Glenner and Wong made the prescient observation that because 
the Aβ peptide deposited in the cerebrovasculature of elderly Down’s syndrome (Trisomy 21) subjects 
was identical (bar an experimental error at one position) to the 21 amino acids that were sequenced 
from sporadic AD (SAD) patients, a genetic defect on chromosome 21 was likely to be a cause of AD 
(Glenner & Wong 1984a).  
Aβ/amyloid pathology is seen in all AD patients, by definition, although its relationship to cognitive 
decline is unresolved  (Arriagada et al. 1992, Delacourte et al. 1999, Naslund et al. 2000). There are now 
hundreds of mutations to three genes, PSEN1, PSEN-2 and APP that can cause early onset familial AD 
(FAD) (http://www.alzforum.org/mutations ).  These mutations all have the effect of increasing the 
amount of C-terminally extended Aβ peptides, or the ratio of aggregatory, longer forms of Aβ to shorter, 
more soluble forms, or to increase the aggregatory properties of the Aβ peptide directly (Citron et al. 
1992, Suzuki et al. 1994, Scheuner et al. 1996, Borchelt et al. 1996, Duff et al. 1996, Bentahir et al. 2006, 
Hori et al. 2007, Inayathullah & Teplow 2011, Ni et al. 2011, Chavez-Gutierrez et al. 2012, Szaruga et al. 
2015).  The longer forms of Aβ are extended at the  C-terminus with  hydrophobic amino acids that 
greatly increase the  propensity for  aggregation  (Jarrett et al. 1993). At this time, several groups made 
the critically important discovery that Aβ was a regular secretion product from cells that expressed the 
APP gene  rather than being produced solely under unusual or physiologically stressful conditions (Shoji 
et al. 1992, Haass et al. 1992, Seubert et al. 1992): this breakthrough enabled the development of cell-
based assays to screen for compounds to inhibit Aβ production.  Ultimately, cell based assays were used 
in the discovery of γ-secretase inhibitors: competitive (Shearman et al. 2000, Esler et al. 2000, Li et al. 
2000); non-competitive (Dovey et al. 2001, Lanz et al. 2006)) and modulator compounds (Weggen et al. 
2001).  The FAD mutations all localize to proteins involved in the production and properties of the Aβ 
peptide.  With respect to SAD, the greatest genetic risk factor is Apolipoprotein (APOE ) 4 (Corder et al. 
1993).  The human population has three major alleles of APOE – APOE2, APOE3 and APOE4  (Nickerson 
et al. 2000).  One allele of APOE4 increases the risk of AD four-fold compared to an APOE3/APOE3 
genotype; two copies of APOE4 increases the risk approximately 12-fold and the APOE2 allele reduces 
risk compared to APOE3 (Verghese et al. 2011).  While the biology of ApoE is undoubtedly complex (Liu 
et al. 2013, Holtzman et al. 2012), there is very strong evidence that show that ApoE is required for the 
deposition of amyloid from preclinical (Bales et al. 1999, Holtzman et al. 2000, Holtzman et al. 1999) and 
clinical (Schmechel et al. 1993, Jack et al. 2015)studies.  Moreover, the increased probability of having 
brain amyloidosis matches the ApoE isoform dependent risk of succumbing to AD.  Additional evidence 
for the primacy of the role of Aβ in AD comes from the A673T mutation (Jonsson et al. 2012) that 
significantly protects against AD.  This mutation (Figure 1) decreases both the production and 
aggregatory properties of Aβ (Maloney et al. 2014, Benilova et al. 2014).   
In summary, the ACH accommodates a wide range of data that we have on AD into a coherent 
hypothesis.  It is worth articulating three tenets that have to be true if ultimately we will refute the null 
hypothesis.   
1. The parenchymal deposition of the Aβ peptide is important pathophysiologically. 
2. Aβ peptide deposition occurs prior to the frank neuronal and synaptic loss that is the hallmark of 
AD.  
3. The evidence from mutations that cause FAD is informative and relevant to SAD.  
Taking each in turn, (1) is to a certain extent a matter of semantics.  As a definite diagnosis of AD relies 
on neuropathologic evidence revealing Aβ plaques and NFTs, presence of deposited Aβ peptide is by 
definition required.  However, the role of deposited Aβ peptide as being the preeminent disease-causing 
Aβ species has been brought into question by the burgeoning literature on smaller molecular weight 
oligomeric Aβ (oAβ) (see later).  Thus, it could be argued that the deposition of Aβ is irrelevant to the 
disease process as such, or at least of much lesser importance.  (2) is likely true although now open to a 
different interpretation.  The ACH as originally conceived placed amyloid as upstream of tau pathology, 
and yet detailed neuropathological studies have shown that tau pathology is present from a very early 
age in some people and in all cases precedes amyloid pathology (Braak et al. 2011).  However, 
correlative studies have shown that amyloid pathology likely drives tau pathology from restricted 
allocortical sites to proliferate throughout the cortex leading to widespread neuronal loss (Price & 
Morris 1999).  (3) is still a matter of significant debate, but it seems very likely that the familial and 
sporadic forms of the disease are identical in all major respects.  For example, the neuropathology of 
SAD and FAD are indistinguishable from each other (Nochlin et al. 1993, Lippa et al. 1996).  Thus, for the 
diseases to be fundamentally different, it would be necessary to explain why the pathological changes in 
a FAD brain lead to a different disease process than in a SAD brain.  Furthermore, as stated previously, 
the greatest genetic risk factor for SAD is carrying an APOE4 allele which also brings forward the age of 
onset for the disease (Corder et al. 1993).  In very large cohorts of FAD patients that all carry the same 
PSEN1 mutation, it has been demonstrated that the APOE4 allele also brings forward the age of onset 
(Pastor et al. 2003).  If SAD and FAD were very different diseases, it would be unlikely that they would 
both be subject to the same genetic modifier.   
Before exploring some of the deficiencies in the ACH, it is worth briefly considering alternative 
hypotheses that have been posited for the onset and progression of AD. 
 
Mitochondrial cascade hypothesis 
 
The mitochondrial cascade hypothesis (MCH) posits that age-related mitochondrial dysfunction 
ultimately leads to the pathology and symptomatology of AD (Swerdlow & Kahn 2004, Swerdlow et al. 
2014).  It also attempts to resolve the difficult question of whether SAD is a usual, but not necessarily 
universal, consequence of brain aging. Indeed, in very elderly cohorts the prevalence of AD pathology 
may exceed 50% (Polvikoski et al. 2001). There is little doubt that there is evidence of mitochondrial 
damage in the brains of people suffering from AD (Lin & Beal 2006).  Furthermore, fluorodeoxyglucose 
positron emission tomography (PET) imaging has revealed deficits in the AD brain quite early on in the 
disease process, which as a marker of oxygen uptake is likely affected due to alterations in 
mitochondrial function (Jack et al. 2012).  Also, there is abundant evidence of increases in free radical 
damage in AD brains that again might result from dysregulated mitochondrial function (Sonnen et al. 
2008).  Some of the experimental support for the MCH comes from the use of cybrids which is where a 
cell line is treated with ethidium bromide to block mitochondrial DNA replication to from a ‘p0’ cell.  
These cells are then co-cultured with platelets  from a human host (e.g., with AD) in the presence of 
polyethylene glycol that induces the transfer of platelet mitochondria into the p0 cells to form a cybrid 
(King & Attardi 1989) – a cell containing mitochondria from a different cell.  Experiments with AD cybrid 
cells have shown an increase in Aβ production (Khan et al. 2000) and reactive oxygen species (Cardoso 
et al. 2004).  The MCH uses such data to suggest that a mitochondrial deficiency in AD brains underpins 
an increase in Aβ production.  In the MCH, Aβ is a biomarker for brain aging, but not a cause of AD as 
such.    
In our opinion, the MCH fails to answer some key questions.  Despite very large genome wide 
association studies (GWAS), no genes that encode mitochondrial proteins or proteins involved in bio-
energetics have been found (Lambert et al. 2013).  Some of the  evidence in support of the MCH comes 
from cell biological systems that are significantly manipulated and might not reflect the human 
pathophysiological situation.   For example, demonstrating that cybrid cell cultures show an increase in 
Aβ production does not reflect the situation in SAD, or, in most cases, in FAD, where the majority of 
mutations alter the ratio of Aβ metabolites or their propensity to aggregate, but do not increase the 
absolute amount – indeed, many reduce overall Aβ production (Chavez-Gutierrez et al. 2012, Szaruga et 
al. 2015). The MCH fails to account for the A673T mutation in APP (Jonsson et al. 2012) that has been 
demonstrated to protect against SAD by reducing Aβ production modestly and reducing its propensity to 
aggregate (Jonsson et al. 2012, Benilova et al. 2014, Maloney et al. 2014). One of the tenets of the MCH, 
that AD is largely a disease of aging, can also be questioned on several levels.  For example, none of the 
genes that causes FAD is known to play a role in aging, and none of the mutations that causes progerias 
results in accelerated AD pathology (Nelson et al. 2011).  Critically, the MCH does not articulate how 
mitochondrial dysfunction leads to the full panoply of AD pathology, which is something it shares in 
common with the ACH.   
 
Dual Pathway Hypothesis. 
 
The dual pathway hypothesis (DPH) (Small & Duff 2008) seeks not to refute the ACH as such, but more 
to refine it especially insofar as SAD is concerned.  Part of the motivation for so doing is based on the 
failure of drugs targeting amyloid (amyloidocentric) to provide therapeutic benefit.  In fact, from the 
time the DPH was published, the litany of failure for amyloidocentric drugs has significantly worsened 
(Karran & Hardy 2014, Cummings et al. 2014).  Post mortem data from patients that participated in the 
Phase 1 AN1792 study (Nicoll et al. 2003, Holmes et al. 2008, Paquet et al. 2015), where amyloid was 
apparently cleared from the brains of patients but cognitive decline proceeded unabated, is used to 
support the view that amyloid deposition in SAD does not necessarily drive other pathologies, as is 
implicit in the ACH.  The DPH posits that there might be upstream factors that are able to drive both the 
major pathologies, amyloid and tau, such that treatments downstream of these factors will not 
ultimately provide therapeutic benefit.  The data supporting potential upstream mechanisms includes, 
for example, ApoE4, which might act to increase Aβ deposition via reduced clearance and increase tau 
phosphorylation via low-density lipoprotein receptor related protein (LRP)5 and LRP6 signaling to 
activate glycogen synthase kinase 3β activity.  
However, and as pointed out by the authors, the data supporting ApoE4 mediating its effects via Aβ are 
very compelling and more substantive than are the links to tau pathobiology.  Further, the phenotypic 
effect of ApoE4 to bring forward the age of onset for AD is present in both SAD and FAD (Pastor et al. 
2003), strongly implying that SAD and FAD are similar disease processes.  Finally, from neuropathological 
and clinical correlations, tau pathology is better correlated with both neuronal loss and symptomatology 
(Arriagada et al. 1992, Gomez-Isla et al. 1996).  If ApoE4 was driving both pathologies, one might 
anticipate that ApoE4 would bring forward the age onset of disease and accelerate disease progression: 
while there is excellent evidence for the former, there are little data to support the latter.  Nevertheless, 
the DPH seeks to resolve the disconnection between amyloid and tau pathology and to explore the 
upstream triggers for disease in SAD, which is totally unexplained by the ACH. 
 
The Metabolism Hypothesis 
 
The metabolism hypothesis (MH) has its origins the work of Hoyer and colleagues (Hoyer et al. 1988, 
Hoyer 1991) who believed that the underlying cause of AD was cerebral glucose hypometabolism.  To 
investigate this phenomenon they developed a rat model that involved injecting streptozotocin 
intracerebroventricularly into rats (Lannert & Hoyer 1998). This resulted in decreased glucose/energy 
brain metabolism together with learning and memory deficits.  Streptozotocin is an agent widely used in 
the diabetes field to destroy β pancreatic cells in rats to produce an insulin-dependent diabetic state.  
Since these early experimental approaches, a significant body of evidence has grown that indeed 
establishes that insulin signaling in the brain is significantly impaired.  For example, many of the mRNA 
transcripts encoding key elements of the insulin signaling pathway are significantly depressed in 
multiple regions of the AD brain (Steen et al. 2005) leading to the description that AD is ‘Type 3 
Diabetes’.  Proponents of the MH argue that insulin signaling is required for preserving synaptic 
connectivity and may play a role in neuronal stem cell activation and neuronal ‘resilience’.  Some very 
interesting preclinical work has been performed with incretin mimetics such as liraglutide, which when 
administered via intraperitoneal injection to APP Swe/PS1ΔE9 mice (25nmol/kg od) was shown to 
reduce Aβ plaque load significantly (McClean & Holscher 2014).  There are also data that show that Aβ 
oligomers  (oAβ) bind to and antagonize various components of the insulin signaling pathway and that 
this may lead to an increase in activity of GSK-3β, a known tau kinase (Morgen & Frolich 2015).  
Furthermore, as stated earlier, imaging studies using fluorodeoxyglucose PET brain imaging, which is a 
measure of glucose uptake and neuronal activity, reveals deficits very early on in the clinical course of 
AD patients (Jack et al. 2011). 
It is difficult to extrapolate the findings from the streptozotocin rat experiments to AD: there is very little 
face or construct validity given the relatively non-specific mechanism of action of the toxin.  The role of 
oAβ to provoke insulin signaling abnormalities is rather weak, mainly because the role of oAβ 
themselves is controversial (Benilova et al. 2012). It is difficult to assign a primary role of insulin signaling 
abnormalities in disease causation as currently there are no data from GWAS studies to support such a 
role (Lambert et al. 2013), and the data that place insulin signaling abnormalities upstream of tau and 
amyloid pathology are not yet compelling.  It may be the case, however, that insulin signaling pathways 
are adversely affected due to the AD disease process itself, and in general this hypothesis has merit 
because it provides a number of testable hypotheses and avenues for therapeutic intervention. Indeed, 
there have been a number of small clinical experiments where insulin has been delivered directly intra-
nasally into the brain with promising results (Bedse et al. 2015, Craft et al. 2012), leading to a much 
larger clinical trial that is underway (ClinicalTrials.gov Identifier:NCT01767909).  
 
Cell-Cycle Re-entry Hypothesis 
 
The cell-cycle re-entry hypothesis (CCRH) might be considered a particular form of a more general 
hypothesis that posits that an age-related increase in DNA damage in neurons is responsible for 
neurodegenerative disease (Chow & Herrup 2015).  Neurons are post-mitotic cells and therefore need to 
sustain their genomic integrity for life.   Neurons might also be subject to significant stressors during life: 
being cells with a very high energy requirement, the potential for DNA damage via reactive oxygen 
species is significant coupled with the  errors that can result from gene transcription (Poduri et al. 2013, 
Lodato et al. 2015).  The first indications of a potential role for aberrant cell cycling in the brain came 
from observations demonstrating that mitogen kinases had increased expression in the AD brain (Arendt 
et al. 1995) and that specific antibodies raised to paired helical filaments (PHFs) of tau purified from AD 
brain cross-reacted with epitopes in dividing cells (Vincent et al. 1996).  Further work revealed that 
driving primary, differentiated neurons to divide by infecting with oncogenes c-myc and ras resulted in 
DNA duplication and increases in both anti-phospho-tau immunoreactivity and AD-like abnormally 
folded tau epitopes (recognized by ALZ50 antibody) (McShea et al. 2007).  However, the cells did not 
enter mitosis, suggesting that the cells get blocked at the G2/M transition.  The c-myc oncogene was 
also conditionally expressed in frontal cortex using CaMKII-tTa transgenic mice crossed to tet-o-Myc 
transgenic mice (Lee et al. 2009).  c-Myc expression was initiated by removing doxycycline from the diet.  
The bigenic mice showed markers of cell cycle activation, DNA replication, hippocampal neuronal loss 
and cognitive behavioral deficits. Surprisingly, given previous work, evidence for abnormal tau 
phosphorylation was not presented.  In post mitotic neurons, DNA repair is afforded by a variety of 
mechanisms which if disrupted can result in a number of serious neurological abnormalities including 
neurodegeneration (McKinnon 2013) but these are mostly early onset developmental conditions.  
Linking frustrated mitotic cell division to the range of neuropathology evident in AD is currently 
challenging.  While a plausible link to tau pathology can be made, the data suggesting a role for cell cycle 
re-entry in Aβ deposition is not substantial.  Further, there is currently no human genetic evidence from 
GWAS studies that support a role for aberrant cell-cycle re-entry (Lambert et al. 2013), and it is difficult 
to reconcile the effect of the A673T APP mutation to protect against AD into this schema (Jonsson et al. 
2012).  
 
Vascular hypothesis 
 
The vascular hypothesis (VH) was originally based on the neuropathological observations that the AD 
brain has a disorganized and much reduced capillary and vascular network (Fischer et al. 1990, de la 
Torre & Mussivand 1993).  There is now a significant body of evidence that supports an important role 
for the brain’s vascular system in AD (de la Torre 2004, Marchesi 2011). Some of the known risk factors 
for AD include hypertension in midlife and diabetes in late-life (and probably in midlife) both of which 
have significant vascular morbidities (Prince et al. 2014).  A study of the localization of thioflavine T-
staining amyloid plaques in a range of dementias (AD, Pick's disease, Guam amyotrophic lateral 
sclerosis/parkinsonian dementia complex,  Down syndrome,  dementia pugilistica and prion disease) 
revealed significant reductions in the microvasculature and some co-localization of blood vessels and 
plaques (Buee et al. 1994).  This latter aspect was investigated more thoroughly and the co-localization 
of haem-rich deposits, amyloid plaques and blood vessels was demonstrated in AD and Down’s 
syndrome brains (Cullen et al. 2006).  A very thorough investigation of this relationship was performed 
using the TG2576 and the PSAPP transgenic mouse models that both develop parenchymal amyloid 
deposition (Kumar-Singh et al. 2005).  These studies revealed that 85-95% of dense core plaques were 
either centered on, or adjacent to, vasculature vessel walls.  Interestingly, the same was not true for 
diffuse amyloid.  However, in both these models the Aβ composition of the plaques is dominated by the 
Aβ40 species, unlike AD plaques which are made predominantly of Aβ42 (Welander et al. 2009).  Aβ40 is 
more soluble than the Aβ42 and more likely to be able to be trafficked to the vasculature via bulk 
interstitial fluid flow.  However, these studies cannot confirm a temporal relationship – do amyloid 
plaques result in vascular damage, or does vascular damage result in plaques?  To investigate this 
aspect, the generation of plaques was investigated using electron microscopy and the earliest signs of 
fibrillary Aβ appeared to form in the perivascular space.  This work relates importantly to the clearance 
of Aβ from the brain: clearly, if extracellular concentrations of Aβ are kept low, the potential for 
aggregation will likely be diminished.  A detailed analysis of brain clearance mechanisms is beyond the 
scope of this review (see (Weller et al. 2008, Tarasoff-Conway et al. 2015)) but there have been some 
recent important developments.  A clearance pathway – the glymphatic system – has been described for 
the first time (Iliff et al. 2012) that is part of the Aβ clearance mechanism.  The glymphatic (glial-
lymphatic) system consists of perivascular conduits formed by glial cell end-feet.  Interestingly in the 
context of AD, these glial processes are also a site of ApoE expression.  Fluid is believed to be impelled  
through the glymphatic system at least in part by the pulsatile contraction of smooth muscle cells in the 
vasculature, providing a potential mechanistic link with the vascular system.   There are several aspects 
of the VH that integrate multiple elements of features of AD: the known co-morbidities, the important 
role in Aβ clearance and providing potential sites for initial Aβ deposition.  However, what is difficult to 
determine is primacy of effect.  Does a vascular insufficiency leading to impaired Aβ  clearance, or local 
vascular damage, provide the appropriate local environment for amyloid deposition, or does amyloid 
deposition result in vascular damage: or can it be both?   
 
Aβ Oligomer Hypothesis 
 
The Aβ Oligomer Hypothesis (ABOH) is a variant of the original ACH that currently has significant 
momentum (Walsh & Selkoe 2007).  The ABOH posits that small molecular weight oAβ represent 
neurotoxic agents that cause synaptic damage in AD.  There are significant attractions to the ABOH, 
principle amongst which is a potential resolution of a major conundrum of AD research: amyloid plaques 
do not correlate in terms of their amount, nor brain regional location, with AD symptomatology or 
neuronal loss (Gomez-Isla et al. 1996, Delacourte et al. 1999).  Indeed, it is difficult to visualize how very 
insoluble, relatively inert protein deposits are able to exert a damaging effect on the brain.  Thus, oAβ 
might act at a distance from plaques and mediate toxic effects.  There are wealth of data, beyond the 
scope of this review, that together provide a large body of supportive data for the ABOH.  These include:  
the manufacture of various aggregated forms of Aβ in vitro, using Aβ42, Aβ40, ratios, and modified 
forms thereof at supra-physiological concentrations to make oAβ; the profiling of these using analytical 
techniques such as size exclusion chromatography, sodium dodecyl sulfate - poly acrylamide gel 
electrophoresis gels (SDS-PAGE) and EM imaging; the treatment of in vitro neuronal cell cultures with 
(usually) supra-physiological concentrations  to induce neuronal cell distress; the investigation of oAβ to 
affect a number of important neuronal receptors (eg, Insulin R, nicotinic receptors); the treatment of 
brain slice preparations to induce electrophysiological changes such as reduction or abolition of LTP; the 
injection of oAβ into rodent brains to induce impaired cognitive functioning (Haass & Selkoe 2007, 
Ferreira & Klein 2011, Koffie et al. 2011, Mucke & Selkoe 2012, Hayden & Teplow 2013, Hefti et al. 2013, 
Viola & Klein 2015).  Also, there have been attempts to categorize oAβ in APP transgenic mice using anti-
oAβ conformational antibodies (Liu et al. 2015).  The ABOH, if true, would also have a profound effect 
on clinical development, as it could mean that therapeutics that are targeting amyloid plaque would not 
be efficacious, and indeed might be positively deleterious if by disaggregating plaques they released, or 
created favourable conditions for, increased levels of oAβ.  Despite these data, and significant support in 
the AD research field generally, there a number of fundamental questions that remain to be answered 
with respect to the ABOH (Benilova et al2012).  Hepler and colleagues (Hepler et al. 2006) have shown 
convincingly that aggregated Aβ runs aberrantly in size exclusion chromatography, mainly because 
monomeric Aβ does not perform as a solvated sphere.  Further, these workers have shown SDS-PAGE 
cannot be used to resolve different Aβ species unequivocally, and also that the appearance of oAβ in 
electron microscopy is heavily dependent on the properties of the surface upon which the Aβ 
aggregates are dispersed. Thus, many analytical procedures routinely used in the field are confounded. 
The interpretation of neuronal cell death induced by oAβ in vitro is also problematic.  Often, such 
experiments use neuronal cell lines or primary rodent neurons to demonstrate Aβ-mediated cell distress 
and death, sometimes in a manner that discriminates between different oAβ forms (Ono et al. 2009, 
Ahmed et al. 2010).  However, in APP transgenic mouse models, which reveal plaque pathology that is 
very similar to that seen in AD, neuronal loss is usually completely absent (Irizarry et al. 1997a, Irizarry et 
al. 1997b).  Thus, human Aβ can be toxic to rodent neurons in vitro, but often not in vivo.   
The most challenging of these questions is to provide unequivocal evidence of their existence, and role, 
in the AD brain.  Attempts to measure oAβ in intercellular fluid in brain parenchyma of transgenic mice 
that develop Aβ plaque pathology have been very technically challenging (Hong et al. 2014) as have 
measurements of oAβ in cerebrospinal fluid from AD patients.  Indeed, recent work with sensitive assays 
has failed to reveal a difference between oAβ concentrations in AD versus controls (Yang et al. 2015).  
These studies have been confounded by a lack of a biophysical definition of an oligomer and no standard 
preparation of a single species with which to calibrate and control assays.  It is important, in this context, 
to distinguish between measuring oAβ, and extracting oAβ.  There are multiple papers that use various 
techniques to extract a range of oAβ species from AD brains that can be subsequently revealed on 
denaturing SDS-PAGE, followed by Western blotting using anti-Aβ antibodies (Ward et al. 2000, 
Upadhaya et al. 2012). However, these techniques likely create oAβ species due to the physicochemical 
properties of the Aβ peptide as discussed earlier.  Leaving aside these issues, perhaps the most 
compelling evidence for a role of oAβ could be inferred from human genetics - indeed, the V717I 
mutation that causes FAD provided the cornerstone for the amyloid cascade hypothesis (Goate et al. 
1991). The APP gene has a wide range of different mutations (http://www.alzforum.org/mutations) that 
cause FAD and/or congophilic amyloid angiopathy (Figure 1).  These can be either N-terminal or C-
terminal to, or within, the Aβ42 peptide.  A consideration of the latter is particularly instructive because 
these are unlikely to affect the production of Aβ or the ratio of long to shorter forms that has been 
shown previously to be important in age of disease onset (Duering et al. 2005, Kumar-Singh et al. 2006).  
Mutations within the Aβ42 peptide are more likely to affect the folding of the peptide, although other 
aspects may also be affected, such as clearance from or degradation within the brain. However, a 
mutation that locked the Aβ peptide in an oAβ from, or greatly inhibited the formation of amyloid fibrils 
so as to increase the proportion of oAβ, would add significant weight to the ABOH.   
The amino acid position 2 of the Aβ sequence (with the N-terminal Aβ aspartic acid = 1) is particularly 
interesting as it has both protective (A2T) (Jonsson et al. 2012) and disease-causing (A2V) mutations (Di 
Fede et al. 2009) (Figure 1).  A2T results in a 50% reduction in Aβ production when over-expressed in 
primary mouse neuronal cells, which would equate to a 25% reduction in the heterozygotic state 
(Benilova et al. 2014). A2V, found as an autosomal recessive mutation in humans, approximately 
doubles production of Aβ by rendering APP a better substrate for β-secretase.  However, both 
mutations also have effects on the aggregatory properties of the Aβ peptides that were revealed using 
synthetic Aβ40 preparations.  Effects on Aβ42 were not informative for largely technical reasons: at the 
concentrations of Aβ used in these experiments, Aβ42 forms amyloid fibrils very rapidly compared to 
Aβ40 making dissection and measurement of aggregation very challenging.  The protective A2T 
mutation increased the lag phase prior to aggregation and the change in Gibbs free energy compared 
with wild type was lower, demonstrating the reduction in aggregation.  The A2V mutation almost 
abolished the lag phase, such that fibrillar amyloid was being formed almost immediately.  Interestingly, 
antibodies that have been reported to be conformational, ‘oAβ specific’ (A11 and OC) (Kayed et al. 
2007) failed to recognize either mutant Aβ in the soluble phase post-fibrillization despite a range of 
small Aβ species being visualized using electron microscopy. This finding rather casts doubt on the 
validity of these antibodies to measure oAβ specifically.  Similar work was published using Aβ42 peptides 
(Maloney et al. 2014). Hori and colleagues (Hori et al. 2007) studied the effects of the H6R, D7N and 
E22G mutations.  All the mutations increased the rate of formation of fibrillary amyloid, but this was 
mediated differently.   In the case of E22G, both seeding/nucleation and amyloid fibril elongation was 
increased significantly compared to wild type Aβ.  This led to increases both in protofibril and fibril 
formation. The effects of the H6R and D7N mutations were to increase significantly amyloid fibril 
enlongation rate – that is, the rate at which monomers are added to the growing amyloid fibril. 
However, this led to very significant reduction in the concentration and residence time of oAβ species: 
presumably, the addition of monomers to existing amyloid fibrils was energetically more favourable 
than the formation of oAβ and protofibrils.    
The ΔE22 mutation initially caused significant excitement in the field because the first reports suggested 
that the phenotypic effect was to promote oAβ formation and prevent Aβ fibril formation (Tomiyama et 
al. 2008).  However, subsequent work revealed that this was likely an assay artefact (Inayathullah & 
Teplow 2011).  The effects of the ΔE22 mutation are two-fold: firstly, there was an increase in the 
formation of oAβ species.  However, this effect was dwarfed by an extraordinary increase in the 
propensity of the mutant to form β-pleated sheet fibrillar amyloid that was ~400-fold faster than wild 
type.   
A comparative study of the A21G, E22G, E22Q, E22K and D23N mutations (Ni et al. 2011) showed that all 
of these species were able to form β-pleated sheet amyloid fibrils. With the exception of A21G, all of the 
mutants decreased the lag phase for the formation of Aβ fibrils, some of them dramatically (E22Q, 
D23N).  A21G resulted overall in an increase in total fibrillization, as did E22Q. It is important to note 
that these mid-domain changes may have other effects as well: for example, these mutations can cause 
cerebral amyloid angiopathy as well as AD, implying changes in clearance mechanisms (Van 
Broeckhoven & Kumar-Singh 2006, Zhang-Nunes et al. 2006).   
 
In conclusion, the effects of the mid-domain Aβ mutations on aggregation do not provide data in 
support of the OABH, although caution is warranted in extrapolating from very artificial biochemical 
systems to the complexity of the human brain.  Nonetheless, if anything the mid-domain mutations tend 
to increase the propensity of Aβ to form amyloid rather than oAβ.   A compelling role for oAβ-type 
species is in the seeding of amyloid plaques.  A wealth of careful and compelling science from Walker 
and Jucker, and others, have unequivocally demonstrated that a soluble Aβ species is able to seed Aβ 
plaque deposition (for review, see (Walker & Jucker 2015).  Furthermore, these species are very stable, 
long lived and prion-like (Ye et al. 2015).  The seeding of Aβ plaque in humans has also recently been 
postulated as a consequence of the treatment of humans with extracts from pituitary glands 
(Jaunmuktane et al. 2015) or with dura mater grafts (Frontzek et al. 2016) although caution must be 
exercised in interpreting these data given the very heterogeneous nature of the implanted tissues.   
 
For each of the hypotheses considered here, including the ACH, rejection of the null will require firstly, 
the development of a specific therapeutic approach that addresses a key mechanism that is predicted by 
the hypothesis to be pathological, and secondly, the demonstration that the therapy has efficacy in a 
placebo-controlled, randomized clinical trial in AD patients. Also, it is important to distinguish between 
the causes of AD, and the consequences of the AD process.  It is likely that many of the processes that 
are featured in the various hypotheses previously considered do play a role in AD, but they do not 
initiate the disease. 
A version of the ACH hypothesis is provided ( Figure 2) that we believe reflects, parsimoniously, the 
current state of knowledge.  There are still a significant number of gaps in the ACH, many of which have 
been attacked by detractors of the hypothesis (Herrup 2015) and that we will address where possible. 
 
Disease initiation 
 
In SAD and FAD we do not know what initiates Aβ deposition.  The ACH has sometimes been interpreted 
to suggest an increase in Aβ production results in AD, and indeed there are data that support this view 
(Potter et al. 2013) but in fact the majority of FAD mutations do not result in an increase in Aβ 
production, but an increase in the ratio of the longer to the shorter forms of the Aβ peptide (Citron et al. 
1992, Suzuki et al. 1994, Scheuner et al. 1996, Borchelt et al. 1996, Duff et al. 1996, Bentahir et al. 2006, 
Chavez-Gutierrez et al. 2012, Szaruga et al. 2015).  Also, Aβ is not present at a concentration in 
interstitial fluid at which it can spontaneously aggregate, so it must be a facilitated process.  However, 
there is compelling data that very low abundance, stable, Aβ conformers can seed Aβ plaques as 
previously discussed.  This opens the possibility that a very discrete, local increase in Aβ concentration, 
or a stochastic templating event, could create seeds that ultimately catalyze widespread plaque 
deposition.  Quite possibly, and as mentioned previously, the microvasculature, or the glymphatic 
system, may play important roles in this regard.   
  
Why is not FAD a neurodevelopmental disease? 
 
The mutations that result in FAD are present throughout life but nevertheless have a relatively late age 
of onset.  The explanation for this is likely to reside in some element of brain physiology that changes 
with age and offsets or prevents the initial Aβ seeding event.  For example, several relevant homeostatic 
mechanisms, such as the production of CSF (Rubenstein 1998) and proteostasis decline with age 
(Labbadia & Morimoto 2015), and these, and other mechanisms, could lead to a catastrophic seeding 
event.  The same argument can be made for SAD albeit at a later age.  In this model, initial Aβ seeding is 
a feature of the aggregatory properties of the Aβ peptide coupled to the brain’s compensatory 
mechanisms. 
 
Why is there no correlation between the levels of amyloid Aβ and cognitive impairment? 
 
This issue can be partly understood from the effects of FAD mutations and APOE4 genotype, the effects 
of which are to bring forward, in some cases dramatically, the age of onset of AD but not to accelerate 
the progression of the disease.  This situation is concordant with amyloid Aβ either triggering a disease 
process, or surmounting some threshold before the disease is provoked (reviewed in (Karran et al. 
2011)).  In this case, one would not expect a correlation between Aβ amyloid and cognitive decline.  
Another way of thinking about this question is to consider that AD pathology – both amyloid and tau – 
can be accommodated by the brain by cell driven compensatory mechanisms until there is a deleterious 
cellular response that leads ultimately to system failure (De Strooper & Karran 2016).   
 
What is the connection between amyloid and tau pathologies? 
 
The ACH has no answer to this question currently, and in Figure 2 this is represented by ‘aggregate 
stress’.  However, there are some very intriguing trends.  The discovery that mutations to TREM2 are 
very significant risk factors for AD place the microglial cell centrally in the disease process (Guerreiro et 
al. 2013, Jonsson et al. 2013), an observation that others have made well before the genetic evidence 
was known (McGeer et al. 1988).  TREM2 is a type I transmembrane protein that is expressed on 
microglia.  A study of late onset AD patients versus controls using whole-genome gene-expression 
profiling (Zhang et al. 2013) demonstrated that a module grouping innate immunity/microglia related 
genes correlated best with clinical disease. TYROBP ranked highest as the module’s potential regulator. 
TYROBP, otherwise known as DAP12, encodes the signalling partner for TREM2. Thus, from two 
orthogonal data sources the TREM2/Tyrobp signaling system has been implicated in AD.  Homozygous, 
loss of function mutations in TREM2 and TYROPB cause Nasu Hakola disease that is characterized by 
cystic bone lesions, white matter loss and dementia. TREM2 binds to a range of poorly defined ligands 
such as phospholipids, bacterial products and cell debris and receptor binding mediates microglial 
phagocytosis and promotes an anti-inflammatory cytokine profile (Daws et al. 2003, Cannon et al. 2012). 
The greatest risk for AD is associated with the R47H variant which causes loss of function by preventing 
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normal folding of the protein (Kleinberger et al. 2014). An obvious hypothesis is that TREM2 signalling 
plays a role in the balance of pro-inflammatory responses versus phagocytosis of Aβ plaques 
(Kleinberger et al., 2014).  
A series of GWASs studies has ultimately resulted in the identification of 22 susceptibility loci (Lambert 
et al. 2013) of which a large group clearly are related to  innate immune system regulation: complement 
receptor 1 (CR1), clusterin, CD33, the MS4A6-MS4A4 cluster, ABCA7, CD2AP, EPHA1, HLA-DRB5–DRB1, 
INPP5D and MEF2C  (Karch and Goate, 2014). It is feasible that as the effects of these genes on biological 
systems is unravelled, a pathway between amyloid and tau pathology will be found, and may reside in 
the brain’s inflammatory response to amyloid deposition.  
 
The ACH can be rejected because amyloidocentric drugs have failed 
It a matter of great concern, both to adherents of the ACH and its gainsayers, that none of the 
amyloidocentric drugs tested to date has met their predetermined primary endpoints.  However, it is 
one thing to test a drug and quite another to test a hypothesis.  In a thorough review of the recent 
amyloidocentric drug discovery and development programs that have reached Phase 3 clinical testing 
(Table 1) it was shown that in several cases there was a significant lack of translation from preclinical to 
clinical science, and in only two of the programs – semagecestat and solanezumab – was target 
engagement measured (Karran & Hardy 2014).  However, there has been no doubt that this catalogue of 
failure (Cummings et al. 2014) has been damaging: while several cogent arguments can and have been 
deployed to explain the lack of efficacy of these approaches (eg De Strooper, 2014), nevertheless the 
field may lose patience and the will to continue with amyloidocentric approaches in the absence of 
tangible success.  The field has not been without some encouragement, however.  Solanezumab was 
shown to have a significant effect on cognition in the Expedition and Expedition II trials in mild AD in a 
pre-specified secondary outcome (Siemers et al. 2015), and in a three year ‘staggered-start’ extension 
study following the initial blinded phase, there was evidence for a genuine disease-modifying effect (Liu-
Seifert et al. 2015) .  
Has the ACH been useful? 
Undoubtedly, it has.  The ACH has provided a framework that has underpinned a huge amount of both 
academic and industry science.  While Table 1 makes for sober reading, a huge amount of data and 
experience has been gathered regarding trial design, patient ascertainment, drop-out rates, placebo 
decline, biomarkers, and clinical assessment.  Significant progress has been made in field of biomarkers 
in particular: it is difficult to imagine that the field would have initiated the AD Neuroimaging Initiative 
(Weiner et al. 2010, Weiner et al. 2015) and developed a number of amyloid PET ligands in the absence 
of the ACH.   The field has learned from failure, although more data sharing, especially between 
pharmaceutical companies, would facilitate information dissemination significantly.   
The field has re-defined AD in recognition that amyloid deposition occurs many years prior to the onset 
of symptoms, such that there is now a phase called preclinical asymptomatic amyloidosis (Sperling et al. 
2011). This change in perspective has prompted a significant number of clinical investigations into 
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presymptomatic patients – a move that would have been almost unimaginable not so many years ago, 
but one that is nevertheless supported by our growing understanding of the disease (Reiman et al. 
2016).   
The future: are we poised for success or failure? 
Table 2 gives the current status of amyloidocentric therapeutic approaches in the clinic – an impressive 
list.  The field awaits with great anticipation the results from verubecestat and solanezumab which are 
the most advanced in clinical development.  If either therapeutic meet their primary outcome measures,  
a huge amount of work, in academia and industry, would seem to have been worthwhile, and at long 
last AD patients and those that care for them will have been given hope.  But what if they fail?  The 
effects of FAD mutations are unequivocally to bring forward the age of disease onset: yet there are little 
data to support the case that they accelerate the progression of the disease once initiated (Holmes & 
Lovestone 2002, Godbolt et al. 2004, Snider et al. 2005, Kumar-Singh et al. 2006, Acosta-Baena et al. 
2011, Karran et al. 2011).  As FAD mutations likely all increase the probability of amyloid deposition, it 
could be the case that amyloid deposition triggers, but does not drive, the disease process. The long 
clinical silent phase between amyloid deposition and dementia suggest indeed a complicated process of 
cellular action and reaction, which we have called the cellular phase (De Strooper and Karran, 2016) and 
might lead to secondary, irreversible and damaging disturbances of normal brain homeostasis.  Thus it is 
conceivable that amyloidocentric approaches may only provide therapeutic benefit if they are 
administered prophylactically in a primary prevention-type clinical trial.  In the most challenging clinical 
scenario, and depending somewhat on the mechanism of action of the therapeutic, this would mean 
treating at-risk individuals prior to amyloid deposition and many years before any cognitive symptoms 
are manifest.   If an amyloidocentric therapy failed to act in such a trial, and presuming that it 
demonstrated adequate target engagement,  despite all of the supporting evidence for the ACH, we 
would need to accept the null hypothesis.  Clearly, we hope, and anticipate, that some of therapeutic 
approaches show efficacy well before this type of prevention study is completed.  Realistically, it is 
unlikely that the current agents under phase 3 clinical testing will demonstrate outstanding efficacy, but 
to answer the question posed by the title of this review, we believe that for solanezumab at least we are 
poised for a modest therapeutic benefit, but a very large scientific success.   
 
Table 1. Outcome of Phase 3 clinical trials of amyloidocentric drugs. 
Drug name  Proposed mechanism of 
action. 
Phase 3 results 
Tramiprosate Aß  Small molecule to prevent 
Aβ aggregation. 
1052 mild to moderate AD patients randomized 
to 3 groups: placebo, 100, 150mg/kg bid for 78 
weeks.  No significant effects on primary outcome 
measures of ADAS-cog and CDR-sum of boxes 
(Aisen et al. 2011) 
Tarenflurbil  Small molecule γ-secretase 1684 mild AD patients randomized to placebo, 
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(Green et al. 2009). 
Semagecestat   Small molecule non 
competitive γ-secretase 
inhibitor to prevent 
production of all Aβ species. 
2600 mild-to-moderate AD patients randomized 
to placebo, 100, 140mg semagecestat od for 76 
weeks in two trials (ClinicalTrials.gov identifiers 
NCT00594568; NTC00762411) enrolled.  Trials 
were halted after interim analysis showed 
increased incidence of skin cancer and worsening 
of cognition and activities of daily living (Doody et 
al. 2013). 
Bapineuzumab 
  
Humanized monoclonal 
antibody directed at amino 
acids 1-5 of Aß peptide. 
Mediate amyloid plaque 
clearance via binding to 
plaque and promoting 
microglial activation. 
4500 mild-to-moderate AD patients randomized 
to placebo and 0.5mg/kg IV every 13 weeks for 18 
months in ApoE4 carriers, and randomized to 
placebo and 0.5 and 1.0mg/kg IV every 13 weeks 
for 18 months in ApoE4 non-carriers in four trials 
(Clinical Trials.gov identfiers lNCT00575055;  
NCT00574132; NCT00676143; NCT00667810.) 
Trials were halted after completion of two trials 
demonstrated a failure to meet primary outcome 
measures of cognition and activities of daily living 
(Salloway et al. 2014). 
Solanezumab 
  
Humanized monoclonal 
antibody directed at amino 
acids 16-24 of Aß.  Mediate 
amyloid plaque clearance 
via reduction of free 
concentration of Aβ peptide 
in the periphery and in CSF.  
 2000 mild-to-moderate AD patients randomized 
to placebo and 400mg solanezumab monthly IV 
for 18 months (Clinical Trials.gov identfiers 
NCT00905372; NCT00904683). Trials failed to 
meet their primary outcome measures of ADAS-
cog an ADCS-activities of daily living (Doody et al. 
2014).  A secondary analysis of mild AD patients 
pooled from both trials showed a significant 
effect on cognition (Siemers et al. 2015). An 
extension study revealed that the positive effects 
on cognition in the mild AD group were sustained 
over the next two years providing evidence for a 
disease modifying effect (Liu-Seifert et al. 2015).  
Gammagard® 
Intravenous 
Immunoglobulin  
Mixture of human 
immunoglobulins that were 
believed to reduce 
peripheral Aβ levels. 
Trial data currently unpublished. 390 mild-
moderate AD patients randomized to 0.2g/kg/2 
weeks and 0. 4g/kg/2weeks versus placebo for 18 
months (ClinicalTrials.gov Identifier: 
NCT00818662). Gammagard failed to reach its co-
primary outcomes of ADAS-Cog and ADCS-ADL.   
 
 
 
 
 
 
 
 
 
 Table 2.  Amyloidocentric approaches in Phase 2/3 clinical efficacy testing for symptomatic AD 
Name  Proposed mechanism of action. Company Trial characteristics 
AZD3293 
LY3314814. 
Small molecule BACE inhibitor 
to prevent production of all Aβ 
species. 
AstraZeneca 
Lilly 
ClinicalTrials.gov Identifier: NCT02245737 
Primary outcome measure: change from baseline in the Clinical 
Dementia Rating - Sum of Boxes (CDR-SB) Score in early AD (mild 
cognitive impaiment to mild AD) in a 2 year study. Aβ/amyloid relevant 
inclusion critiera include positive amyloid PET scan or a lumbar 
puncture to assay for abnormally low Aβ CSF.   
Aducanumab 
BIIB037. 
Human monoclonal antibody 
that binds specifically to 
amyloid plaque to facilitate 
clearance. 
Biogen ClinicalTrials.gov Identifier: NCT02477800/ NCT02484547 
Primary outcome measure: change from baseline in the CDR-SB Score 
in early AD (mild cognitive impaiment to mild AD) in a 1.5 year study. 
Aβ/amyloid relevant inclusion critiera include positive amyloid PET 
scan. 
Azeliragon  
PF-04494700,  
TTP488 
Small molecule antagonist of 
the receptor for advanced 
glycation endproducts (RAGE) 
with multiple Aβ –related 
mechanims of action.  
Pfizer, TransTech 
Pharma, Inc., vTv 
Therapeutics LLC 
ClinicalTrials.gov Identifier: NCT02080364 
Co-primary outcome measures: change from baseline in Alzheimer's 
Disease Assessment Scale - Cognitive (ADAS-cog); change from 
baseline in CDR-SB in mild AD a 1.5 year study.   
Gantenerumab Human monoclonal antibody 
that binds to conformational 
epitopes on fibrillar Aβ to 
facilitate clearance. 
Chugai 
Pharmaceutical 
Co., Ltd., 
Hoffmann-La 
Roche 
ClinicalTrials.gov Identifier: NCT0205160. 
Co-primary outcome measures: change from baseline in ADAS-cog;  
change from baseline in Alzheimer's Disease Cooperative Study-
Activities of Daily Living (ADCS-ADL) scores in mild AD in a 2 year study. 
Aβ/amyloid relevant inclusion critiera include lumbar puncture to 
assay for abnormally low Aβ CSF. 
Solanezumab 
LY2062430 
Humanized monoclonal 
antibody directed at amino 
acids 16-24 of Aβ.  Binds 
Eli Lilly & Co. ClinicalTrials.gov Identifier: NCT01900665 
Co-primary outcome measures: change from baseline in ADAS-
cog;change from baseline in ADCS-iADL scores in mild AD in a 1.5  year 
monomeric species to deplete 
free Aβ and reduce amyloid 
plaque. 
study. Aβ/amyloid relevant inclusion critiera include positive amyloid 
PET scan or a lumbar puncture for to assay for abnormally low Aβ CSF. 
 
 
Verubecestat 
MK-8931 
Small molecule BACE inhibitor 
to prevent production of all Aβ 
species. 
Merck ClinicalTrials.gov Identifier: NCT01739348.  
Co-primary outcome measures: change from baseline in ADAS-cog;  
change from baseline in ADCS-ADL scores in mild to moderate AD in a 
1.5 year study. 
   
Figure Legends 
 
Figure 1.  Amyloid precursor protein familial Alzheimer’s disease mutations. 
The diagram shows the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) and γ-secretase cleavage points and the protective and 
pathogenic amino acid changes mediated by APP mutations.  
 
Figure 2.  Modified Amyloid Cascade Hypothesis. 
The scheme shows that the aggregation of Aβ is a key event but it runs in parallel with tau dysfunction.  At some point, amyloid plaque provokes 
increased tau pathology that spreads throughout the brain.  This process is accelerated by widespread deleterious effects to brain cells leading 
to system failure and dementia. 
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